EDAP May 2024 5.000 call
| Previous Close | 2.1500 |
| Open | 1.7000 |
| Bid | 1.0000 |
| Ask | 1.9500 |
| Strike | 5.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 1.7000 - 1.7000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 54 |
GlobeNewswireEDAP Reports First Quarter 2024 Financial Results
Strong Q1 2024 U.S. Focal One® HIFU procedure growth of +92% year-over-year Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023Q1 2024 total revenue of EUR 14.9 million ($16.1 million USD) increased 0.8% over Q1 2023Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT LYON, France, May 16, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the fir
Simply Wall St.EDAP TMS S.A.'s (NASDAQ:EDAP) top owners are individual investors with 56% stake, while 24% is held by institutions
Key Insights Significant control over EDAP TMS by individual investors implies that the general public has more power...
- GlobeNewswire
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy (RP) Functional evaluation criteria show better results with respect to urinary continence and erectile function in patients receiving HIFU therapy versus patients receiving RP Final study results were presented during a plenary session of the AUA focused on paradigm-shifting and practice-changing c
